ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
MammaPrint® Becomes Only Molecular Diagnostic Recommended for Early-Stage Node-Positive Breast Cancer Patients in ASCO-Endorsed Cancer Care Ontario Guidelines
July 01, 2019MammaPrint® Becomes Only Molecular Diagnostic Recommended for Early-Stage Node-Positive Breast Cancer Patients in ASCO-Endorsed Cancer Care Ontario Guidelines. -
Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal
May 22, 2019Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal. -
Agendia’s MammaPrint® and BluePrint® Breast Cancer Tests Selected by Unicancer for French Patients
June 04, 2018Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announce that Unicancer, a hospital group entirely devoted to fighting cancer,
Pharma Sources Insight January 2025
